FDA asks for more time to evaluate Onglyza for approval

04/24/2009 | Reuters

The FDA delayed by three months its approval decision on Onglyza, an experimental diabetes drug from AstraZeneca and Bristol-Myers Squibb. The agency said it needs more time to review Onglyza, although a spokesman for Bristol-Myers said he was not aware of any request from the agency for additional data on the product.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA